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Abstract FGF21 is recently discovered with pleiotropic
effects on glucose and lipid metabolism. However, the
potential protective effect of FGF21 against D-gal-induced
injury in the liver has not been demonstrated. The aim of
this study is to investigate the pathophysiological role of
FGF21 on hepatic oxidative injury and apoptosis in mice
induced by D-gal. The 3-month-old Kunming mice were
subcutaneously injected with D-gal (180 mg kg-1 d-1) for
8 weeks and administered simultaneously with FGF21 (5
or 1 mg kg-1 d-1). Our results showed that the adminis-
tration of FGF21 significantly alleviated histological lesion
including structure damage, degeneration, and necrosis of
hepatocytes induced by D-gal, and attenuated the elevation
of liver injury markers, serum AST, and ALP in a dose-
dependent manner. FGF21 treatment also suppressed D-gal-
induced profound elevation of ROS production and
oxidative stress, as evidenced by an increase of the MDA
level and depletion of the intracellular GSH level in the
liver, and restored the activities of antioxidant enzymes
SOD, CAT, GSH-Px, and T-AOC. Moreover, FGF21
treatment increased the nuclear abundance of Nrf2 and
subsequent up regulation of several antioxidant genes.
Furthermore, a TUNEL assay showed that D-gal-induced
apoptosis in the mouse liver was significantly inhibited by
FGF21. The expression of caspase-3 was markedly inhib-
ited by the treatment of FGF21 in the liver of D-gal-treated
mice. The levels of PI3K and PBK/Akt were also largely
enhanced, which in turn inactivated pro-apoptotic signaling
events, restoring the balance between pro- and anti-apop-
totic Bcl-2 and Bax proteins in the liver of D-gal-treated
mice. In conclusion, these results suggest that FGF21
protects the mouse liver against D-gal-induced hepatocyte
oxidative stress via enhancing Nrf2-mediated antioxidant
capacity and apoptosis via activating PI3K/Akt pathway.
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Abbreviations
FGF21 Fibroblast growth factor 21
D-Gal D-Galactose
AST Aspartate aminotransferase
ALP Alkaline phosphatase
ROS Reactive oxygen species
MDA Malondialdehyde
GSH Glutathione
SOD Superoxide dismutase
CAT Catalase
GSH-Px Glutathione peroxidase
T-AOC Total antioxidation capability
Nrf2 Nuclear factor erythroid 2-related factor 2
TUNEL Terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP nick end labeling
PI3K Phosphoinositide-3-kinase
PBK/Akt Protein kinase B
Introduction
Increasing evidence has demonstrated that oxidants play
important roles in aging [1]. D-Galactose (D-gal) is present
in many food products and can also be synthesized by the
body, where it forms part of glycolipids and glycoproteins.
It is normally metabolized by D-galactokinase and galac-
tose-1-phosphate uridyltransferase, while at levels greater
than normal, D-gal can promote the generation of reactive
oxygen species (ROS) and the formation of advanced
glycation end-products (AGE) within cells, which in turn
result in oxidative stress and cellular damage in animal
tissues. Chronic administration of D-gal-induced changes
resembled natural aging in rodents [2, 3]. More researches
demonstrated that D-gal treatment caused oxidative stress
and mitochondrial dysfunction in the livers of mice and rats
[4, 5]. These oxidative stress-induced damages disrupt
cellular function and membrane integrity, thereby leading
to apoptosis [6, 7].
In the antioxidant defense system, nuclear factor ery-
throid 2-related factor 2 (Nrf2) is one of the most important
transcription factors in regulating multiple antioxidants,
which binds to the antioxidant response elements (AREs)
and has been demonstrated to be a critical transcription
factor in the promoter region of a number of genes, en-
coding for antioxidative and phase 2 enzymes, such as
hemeoxygenase 1 (HO-1) and glutamate cysteine ligase
(GCL), and plays a critical role in the regulation of the
cellular GSH homeostasis [8, 9]. Apoptosis is a form of
programmed cell death and plays an important role in a
variety of physiological and pathological processes [10].
The phosphoinositide-3-kinase (PI3K)-Akt signaling
pathway plays a crucial role in cell growth and cell survival
[11], which can be activated by many types of cellular
stimuli or toxic insults, and can also mediate some of its
survival signals through the Bcl-2 family [12].
Fibroblast growth factor 21 (FGF21), as a member of the
FGF family secreted predominantly by the liver, pancreas,
and adipose tissues is identified as a critical regulator of
long-term energy balance, glucose, and lipid homeostasis
[13–15]. Recently, there is increasing evidence that FGF21
has the function in suppression of inflammation, oxidative
stress, and the fibrotic effect [16–18]. In addition, FGF21
can regulate ketogenesis, gluconeogenesis, and growth
hormone resistance in the liver, and protect against ac-
etaminophen-induced liver failure in mice [19–22]. As
previously described, many researches indicated that
FGF21 exerts a potentially beneficial protective effect on
organ injury. However, little work has been done to explore
the underlying mechanism of hepatoprotective effects of
FGF21 on D-gal-induced liver injury.
It is well known that oxidative stress leads to apoptosis
and apoptosis contributes to liver injury in many acute and
chronic liver injuries [7, 23]. Therefore, the aim of this
study is to explore whether FGF21 protected mouse liver
from D-gal-induced injury by attenuating oxidative stress
and suppressing apoptosis pathway.
Materials and methods
Animals and treatments
Ethics statement
All experiments were carried out in strict accordance with
the recommendations of the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health
and were approved by Harbin Veterinary Research Institute
Animal Care and Use Committee.
Eight-week-old male Kunming mice were purchased
from Wei tong li hua Animal Center (Beijing, China). The
mice were maintained under constant conditions (23 ± 1 C
and 60 % humidity) and had free access to rodent food and
tap water. Eight mice were housed per cage on a 12-h
light/dark schedule (lights on 08:30–20:30). At 12 weeks of
age (37.1 ± 0.6 g), mice were randomly divided into four
groups (n = 8 per group), groups 2-4 received daily subcu-
taneous injection of D-gal (Sigma-Aldrich, MO, USA) at
dose of 180 mg kg-1 d-1 for 8 weeks and group 1 as normal
control with injection of saline (0.9 %) only. Meanwhile,
group 3 and 4 D-gal-treated mice received simultaneously
FGF21 of 5 or 1 mg kg-1 d-1. Then, mice were sacrificed
and the livers were immediately collected, respectively for
experiments or stored at -70 C for later use.
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Histological evaluations
For pathological studies, the liver tissues were fixed in a
fresh solution of 4 % paraformaldehyde (pH 7.4) for 24 h,
then postfixed in 70 % ethanol for at least 12 h. After de-
hydration, the liver was embedded in paraffin blocks.
2-lm-thick sections obtained from each paraffin block
were stained with hematoxylin and eosin (H & E) for
histopathological evaluation under digital light microscope
Leica Camera (Germany).
Liver function test
Serum was obtained by centrifugation at 11009g for
10 min and stored at -80 C until needed. Serum alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase (ALP), total bilirubin (TBIL)
and direct bilirubin (DBIL) levels were measured by im-
muno enzymatic assays.
Assay of ROS
To measure ROS production, the liver ROS generation was
determined in tissue homogenates by using dichlo-
rofluorescein diacetate (DCFH-DA) (Jiancheng Institute of
Biotechnology, Nanjing China) as a probe according to the
previous literature [31]. Briefly, the homogenate was di-
luted 1:20 (v/v) with PBS buffer (200 mM NaCl, 3 mM
KCl, 10 mM Na2HPO3, 2.0 mM KH2PO3 pH 7.4). The
reaction mixture (200 ul) containing 190 ul of homogenate
and 10 ll of 1 mM 20,70-dichlorodihydrofluorescein diac-
etate was incubated for 30 min at 37 C temperature to
allow the 20,70-dichlorodihydrofluorescein diacetate to be
incorporated into any membrane-bound vesicles and the
diacetate group to be cleaved by esterases. The conversion
of 20,70-dichlorodihydrofluorescein diacetate to the
fluorescent product 20,70-dichlorofluorescein was measured
using a spectrofluorometer (PerkinElmer, America) with
excitation at 484 nm and emission at 530 nm. Background
fluorescence (190 ul homogenate, 10 ul PBS absence of
20,70-dichlorodihydrofluorescein) was corrected by the in-
clusion of parallel blanks. ROS formation was quantified
from a 20,70-dichlorofluorescein standard curve, and the
data are expressed as pmol 20,70-dichlorofluorescein
formed/min/mg protein.
Determination of redox status
Assay of MDA level
To determine the activity of MDA, we used a commercial
kit (Beyotime Institute of Biotechnology, Suzhou, China)
to quantify the generation of malondialdehyde (MDA)
according to the manufacturer’s protocol. In brief, the liver
tissues were incubated in the lysate buffer (150 mM NaCl,
1 % N-40, 0.5 % deoxycholate, 1 % Triton X-100, 50 mM
Tris–hydrochloric acid, 2 mM phenylmethylsulfonyl
fluoride, and proteinase inhibitor cocktail, pH 7.4). After
grinding, lysed cells were centrifuged at 10,0009g for
5 min to remove debris. The supernatant was subjected to
the measurement of MDA levels. The MDA levels were
determined at 532 nm using tetra methoxypropane as
standard. The results were expressed as the contents nmol
per mg protein.
Assay of GSH level
GSH content was determined using a thiol-specific reagent,
dithionitrobenzoic acid (DTNB) according to the
manufacturer’s protocol (Nanjing Jiancheng Bioengineer-
ing Institute), and the adduct was measured spectrophoto-
metrically at 420 nm. GSH content was expressed as umol
per mg protein.
Assay of SOD activity
SOD activity was measured using an assay kit (Beyotime
Institute of Biotechnology, Suzhou, China) with nitroblue
tetrazolium substances according to the manufacturer’s
introduction. Absorbance was read at 550 nm and the ac-
tivity of SOD was calculated using the formula: [(control
value - blank value) - (sample value - blank value)]/(-
control value - blank value) 9 2 9 (total volume/sample
volume)/protein concentration.
Assay of GSH-Px activity
GSH-PX activity assay was based on the method of Paglia
and Valentine (1967). tert-Butylhydroperoxide was used as
a substrate. The assay measures the enzymatic reduction of
H2O2 by GSH-PX through consumption of reduced glu-
tathione (GSH) that is restored from oxidized glutathione
GSSG in a coupled enzymatic reaction by GR. GR reduces
GSSG to GSH using NADPH as a reducing agent. The
decrease in absorbance at 340 nm due to NADPH con-
sumption was measured in a Molecular Devices M2 plate
reader (Molecular Devices, Menlo. Park, CA). GSH-PX
activity was computed using the molar extinction coeffi-
cient of 6.22 mM-1 cm-1. One unit of GSH-PX was de-
fined as the amount of enzyme that catalyzed the oxidation
of 1.0 mol of NADPH to NADP ? per minute at 25 C.
Assay of CAT activity
CAT activity was measured using a kit (Jiancheng Institute
of Biotechnology, Nanjing China); the result was
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determined by measuring the intensity of a yellow complex
formed by molybdate and H2O2 at 405 nm, after ammo-
nium molybdate was added to terminate the H2O2 degra-
dation reaction catalyzed by CAT. An enzyme activity unit
was defined as degradation of 1 umol H2O2 per sec per mg
tissue protein, and the enzymatic activity was expressed as
U/mg protein.
Assay of T-AOC activity
T-AOC activity was measured using a kit (Jiancheng In-
stitute of Biotechnology, Nanjing China). The antioxidants
of liver tissues can make Fe3? to Fe2?, and the solid
substances can be formed after Fe2? reacting with
phenanthroline substances. The result can be measured
spectrophotometrically at 520 nm.
RNA isolation and real-time quantitative PCR
Total RNA from the livers was isolated with Trizol (Invit-
rogen), and RNA was reverse transcribed into cDNA using
the reverse-transcription kit (Promega, USA). The cDNA
was used for real-time quantitative PCR (ABI 7500, Applied
Biosystems, Carlsbad, CA, USA) with SYBR Green Master
Mix and melting curve to detect the following genes: c-
glutamylcysteine ligase catalytic subunit (GCL-c: F: GTT
ATG GCT TTG AGT GCT GCA T; R: ATC ACT CCC CAG
CGA CAA TC), glutathione peroxidase-1 (Gpx-1: F: CCA
GGA GAA TGG CAA GAA TGA; R: TCT CAC CAT TCA
CTT CGC ACT T), superoxide dismutase-2 (Sod2: F: TCC
CAG ACC TGC CTT ACG ACT AT; R: GGT GGC GTT
GAG ATT GTT CA), glucose-6-phosphate dehydrogenase
(G6pdh: F: CTG GAA CCG CAT CAT CGT GGA G; R:
CCT GAT GAT CCC AAA TTC ATC AAA ATA G), P21:
(F: GCA GAT CCA CAG CGA TAT CC; R: CAA CTG CTC
ACT GTC CAC GG), Nrf2: (F: GAT CCG CCA GCT ACT
CCC AGG TTG; R: AGC ACA CGT TTA TTC ACG GGT),
and b-actin: (F: ACA TCT GCT GGA AGG TGG AC; R:
GGT ACC ACC ATG TAC CCA GG). The amplified PCR
products were quantified by measuring the calculated cycle
thresholds (Ct) of samples mRNA and b-actin mRNA.
Relative multiples of change in mRNA expression were
calculated by 2-DDCt. The mean value of normal group target
levels became the calibrator (one per sample) and the results
are expressed as the n-fold difference relative to normal
controls (relative expression levels).
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) assay
Kidney tissue was fixed in 10 % formalin and embedded in
paraffin. Fixed liver tissues embedded in paraffin were cut
into 4-um thick. After deparaffinization (using xylene and
ethanol dilutions) and rehydration, the sections were
stained for TUNEL with a DeadEndTM Colorimetric
Apoptosis Detection Kit (Promega, USA) according to the
manufacturer’s instructions. Briefly, each slide was de-
paraffinized and rehydrated, and treated with proteinase K
(20 ug/mL) for 15 min, and then incubated with the
TUNEL reaction mixture containing terminal deoxynu-
cleotidyl transferase (TdT) and digoxigenin-11-dUTP for
1 h. TdT reaction was carried out in a humidified chamber
at 37 C. The endogenous peroxidase was inhibited with
0.3 % hydrogen peroxide for 5 min, and then added
Streptavidin HRP for 30 min at room temperature. After
that 3,3-diaminobenzidine chromogen was applied. He-
matoxylin was used as counterstaining. For the negative
control, TdT was omitted from the reaction mixture.
TUNEL-positive cells were counted in at least 25 randomly
selected fields per group (5 mice per group), and the mean
of TUNEL-positive cells from five fields per mouse liver
was calculated for further statistical analysis.
Western blotting
Liver tissue was homogenized in a Western and IP lysate
buffer containing 0.5 % Triton X-100 and protease-inhibitor
cocktail (Beyotime Institute of Biotechnology, Suzhou,
China) and the resulting lysate was centrifuged at
12,000 rpm and 4 C for 5 min. Aliquots of the supernatant
were removed for protein analysis by the BCA method. For
Nrf2 protein detection, cytoplasmic and nuclear extracts
were prepared using the Nuclear and Cytoplasmic Protein
Extraction Kit (Beyotime Institute of Biotechnology, Suz-
hou, China) according to the manufacturer’s instructions.
The supernatant was incubated at 95 C for 5 min in SDS
sample buffer containing 100 mmol/L DTT, and 20 lg of
the sample was then resolved by 12 % SDS-PAGE at 100 V,
and then transferred to a nitrocellulose membrane (GE
Healthcare). After blocking with 5 % skimmed milk for 1 h,
and incubated overnight at 4 C with the following anti-
bodies: anti-Nrf2, anti-PI3K, anti-phospho-Akt (Ser473),
anti-Akt, anti-caspase-3, anti-Bcl-2 and anti-Bax (1:1000
Cell Signaling Technology, Danvers, MA), anti-Laminb1
(1:5000 Affinity Biosciences), and anti-b-actin (1:3000
Signalway USA). Then followed by a horseradish per-
oxidase-conjugated anti-rabbit or anti-mouse IgG secondary
antibody (1:8000) 1 h at room temperature. Blots were vi-
sualized using an enhanced chemi-luminescence detection
kit (ECL; Thermo Scientific, IL). All experiments were
performed in triplicate and repeated at least three times.
Statistical analyses
Values are expressed as mean ± SD of at least three in-
dependent experiments and analyzed using one-way
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ANOVA followed by Duncan’s Multiple Range Test for
comparisons of group means. All statistical analyses were
performed using SPSS 18 for Windows, and P val-
ues \ 0.05 were deemed to indicate statistical significance.
Results
FGF21 protects mice against D-gal-induced hepatic
dysfunction
The extent of hepatic injury can be evaluated by measuring
the serum activities or levels of ALT, AST, ALP, TBIL,
and DBIL [24]. To determine whether FGF21 can attenuate
the liver damage in the D-gal mice, we measured the ac-
tivities of these parameters of all groups (Fig. 1). Com-
paring with the normal controls, the activities or levels of
serum AST, ALP, TBIL, and DBIL increased significantly
in untreated D-gal mice (P \ 0.01). After 8 weeks treat-
ment by FGF21, these parameters except ALT were sup-
pressed in FGF21-treated groups (P \ 0.01 or P \ 0.05).
FGF21 treatment reduces D-gal-induced histological
damage of the liver in mice
The liver histology was used to determine the protective
effect of FGF21 on D-gal-induced injury. As shown in
Fig. 2, compared with normal controls, D-gal treatment
caused visible histological changes including structure
damage, degeneration, and necrosis of hepatocytes
(Fig. 2a, b). While high dose FGF21 (5 mg kg-1 d-1)
significantly alleviated the liver damage in D-gal-treated
mice (Fig. 2c), low dose FGF21 (1 mg kg-1 d-1) group
showed midrange degeneration of hepatocytes (Fig. 2d).
FGF21 inhibits D-gal-induced oxidative stress
by changing multiple oxidative stress parameters
in mice
Many studies have suggested that the levels of ROS might
be indicators of oxidative stress and stimulating ROS
production is reported as one of the most important
mechanisms underlying the D-gal-induced liver dysfunc-
tion. Our results (Fig. 3a) showed that D-gal-treatment
caused a significant increase of ROS in the liver compared
with normal control group (P \ 0.01). After FGF21 ad-
ministration for 2 months, the ROS levels in the liver tissue
significantly reduced in a dose-dependent manner com-
pared with untreated D-gal mice (P \ 0.01 or P \ 0.05).
We also detected most recognized oxidative damage
product, MDA, which is a by-product of lipid peroxidation
induced by free radicals. Our results (Fig. 3b) showed that
D-gal treatment could induce an increase of the MDA level
in the liver compared with normal controls (P \ 0.01).
This increase was reduced (P \ 0.05) by FGF21 treatment
(5 mg kg-1 d-1 or 1 mg kg-1 d-1).
Next, we detected several key antioxidants which can
scavenge ROS, including enzymatic antioxidants SOD,
CAT, and GSH-Px, and non-enzymatic antioxidant T-AOC
in the liver of D-gal-induced mice (Fig. 3c–f). In our re-
sults, a significant decrease in the activities of these an-
tioxidants was observed in D-gal-treated mice compared
with normal control group (P \ 0.001 or P \ 0.01). Ad-
ministration of FGF21 significantly prevented the D-gal-
induced decrease of enzymatic or non-enzymatic an-
tioxidant activity in the liver (P \ 0.01 or P \ 0.05).
FGF21 attenuates ROS accumulation through
increasing nuclear translocation of Nrf2
and the expression of antioxidant genes in the liver
of D-gal-treated mice
Nrf2 is a transcription factor that regulates the expression
of numerous ROS detoxifying and antioxidant genes. In
order to test whether FGF21 could activate Nrf2, we de-
tected the protein accumulations of Nrf2 in the nucleus. As
shown in Fig. 4a, D-gal treatment significantly inhibited the
protein accumulations of Nrf2 in the liver, and adminis-
tration of FGF21 increased the accumulation of Nrf2 in
nucleus (P \ 0.01 or P \ 0.05), suggesting that FGF21
treatment restores the antioxidant activities in the liver of
D-gal mice by increasing the activity of Nrf2 transcriptional
regulator.
As GSH has been demonstrated to be regulated by Nrf2
[9], we detected the levels of GSH in the liver of all groups.
Comparing with normal controls, the GSH levels in the
liver of D-gal mice were lower (P \ 0.01) (Fig. 4b). Ad-
ministration of FGF21 significantly reversed the decreased
levels of GSH in the liver of D-gal mice in a dose-depen-
dent manner (P \ 0.01 or P \ 0.05). Furthermore, FGF21
also significantly increased mRNA expression of several
antioxidant genes of Nrf2 targets, such as Sod2, Gpx-1,
G6pdh, and GCL-c in the liver of D-gal mice (P \ 0.01 or
P \ 0.05) (Fig. 4c–f), suggesting that FGF21 administra-
tion may exert its protective effect on D-gal-induced ox-
idative stress in the liver by elevating multiple antioxidants
genes.
FGF21 prevents D-gal-induced apoptosis of hepatocytes
We used the TUNEL assay to investigate the protective
effect of FGF21 on D-gal-induced apoptosis (Fig. 5). The
results showed that the number of TUNEL-positive cells in
the liver of D-gal mice significantly increased comparing
with normal controls (P \ 0.01), whereas administration of
FGF21 markedly decreased TUNEL-positive cells in the
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liver of the D-gal mice (P \ 0.01). In addition, No sig-
nificant difference in the number of TUNEL-positive cells
in the liver could be seen between the FGF21-treated mice
(5 mg kg-1 d-1) and normal controls.
FGF21 modulates PI3K-Akt activation
and the expression of caspase-3 and pro-apoptotic
proteins
PI3K/Akt pathway is one of the major intracellular sig-
naling pathways for suppressing apoptosis and promoting
cell survival [26]. To investigate whether PI3K-Akt sig-
naling is involved in the action of FGF21, we determined
the effects of FGF21 on PI3K/Akt pathway in the mouse
liver. Western blotting (Fig. 6a–d) revealed that the levels
of PI3K and phospho-Akt (Ser473) markedly decreased in
the livers of D-gal mice as compared with the normal
controls (P \ 0.01). However, the down-regulation of
PI3K and phospho-Akt (Ser473) was markedly reversed by
treatment with FGF21 (P \ 0.01 or P \ 0.05). There were
no significant changes of total Akt levels among all groups.
PI3K/Akt has been shown to regulate the expression of
pro-apoptotic and anti-apoptotic members of the Bcl-2
family such as Bcl-2 and Bax, suggesting the involvement
of the mitochondrial intrinsic pathway of apoptosis [27].
Therefore, we examined the effects of FGF21 on Akt-
Fig. 1 Effect of FGF21 on D-
gal-induced changes in hepatic
functional markers. Normal
controls were treated with saline
(0.9 %), and D-gal mice were
treated with D-gal daily for
8 weeks. FGF21-treated D-gal
mice (D-gal ? FGF21) were
treated with D-gal and
simultaneously administrated
with FGF21 sc at doses of 1 or
5 mg kg-1 d-1 once a day for
8 weeks. a AST activity; b ALT
activity; c ALP activity; d TBIL
levels; e DBIL levels. All these
parameters were measured by
commercial detection kit. All
data are represented as
mean ± SD, n = 8 per group.
*P \ 0.05, **P \ 0.01 and
***P \ 0.001 versus D-gal
group
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regulated intrinsic pro-apoptotic proteins. As shown in
Fig. 6e and h, D-gal caused a reduction in the expression of
the anti-apoptotic protein Bcl-2 (P \ 0.01) and increased
the mitochondrial translocation of Bax in the mouse liver
(P \ 0.01). However, FGF21 treatment abolished the D-
gal-evoked pro-apoptotic signaling events in the liver of
mice (P \ 0.01 or P \ 0.05).
Caspase-3 is one of the key executioners of apoptosis,
capable of cleaving or degrading many key proteins such as
nuclear lamins, fodrin, and the nuclear enzyme poly
(ADPribose) polymerase (PARP) [28]. To determine the
effects of FGF21 on caspase-3 activation, we detected
endogenous levels of the large fragment (17/19 kDa) of
activated caspase-3 in the mouse liver (Fig. 6i, j). Com-
paring with the normal controls, the levels of activated
caspase-3 were significantly elevated in the liver of D-gal
mice (P \ 0.01). Treatment with FGF21 inhibited this
elevation in a dose-dependent manner (P \ 0.01 or
P \ 0.05).
The p21 protein is thought to be a major effector of p53
activity in senescent cells, which induces apoptosis or
telomere loss [29]. In the mice livers, p53/p21 activation
primarily results in cell cycle arrest [30]. As shown in
Fig. 6k, our results showed that the mRNA expression of
P21 significantly increased in the liver of D-gal mice
(P \ 0.01). Administration of FGF21 (5 mg kg-1 d-1)
attenuated the increase of P21 in the liver of D-gal mice
(P \ 0.05).
Discussion
The liver is a major organ involved in D-gal metabolism
and D-gal treatment is found to increase hepatic MDA
levels and cause DNA damage together with oxidative
stress [31]. Age-related disease model, such as liver injury,
induced by D-gal treatment (100–500 mg/kg body weight;
s.c.) for 8 weeks to rats or mice has been widely accepted
[24, 25, 31]. The chronic subcutaneous administration of D-
gal for 7 weeks induces oxidative stress and hepatopathy in
mice and significantly decreases the hepatic superoxide
dismutase and glutathione peroxidase activities [32].
However, there is no report about the FGF21 protective
effects on liver injury induced by D-gal.
Previous studies have shown that treatment with D-gal
causes liver injury and dysfunction, followed by elevated
activities or levels of serum enzymes and histopathological
damage [24, 25, 31, 32]. Our results also showed that the
activities or the levels of AST, ALP, TBIL, and DBIL in
the serum of D-gal mice were markedly increased.
Fig. 2 Effect of FGF21 on histopathological changes of the D-gal-
treated mouse liver. Normal controls were treated with saline (0.9 %),
and D-gal mice were treated with D-gal daily for 8 weeks. FGF21-
treated D-gal mice (D-gal ? FGF21) were treated with D-gal and
simultaneously administrated with FGF21 sc at doses of 1 or
5 mg kg-1 d-1 once a day for 8 weeks. a Normal control; b Mouse
treated with D-gal at dose of 180 mg kg-1 d-1; c FGF21-treated D-gal
mice (D-gal ? FGF21) (5 mg kg-1 d-1). d FGF21-treated D-gal mice
(D-gal ? FGF21) (1 mg kg-1 d-1). The black arrow indicates hep-
atic cell necrosis. The green arrow indicates the leukocytes. Original
magnification, 10 9 20. (Color figure online)
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Moreover, histological changes of the liver, such as
structure damage, degeneration, and necrosis, had been
observed. In this study, treatment with FGF21 effectively
protected mice against D-gal-induced liver damage as
indicated that the activities or the levels of serum AST,
ALP, TBIL, and DBIL decreased and hepatic histological
changes were alleviated, suggesting a protective effect of
FGF21 against D-gal-induced liver injury.
Many studies demonstrate that possible molecular
mechanism involved in D-gal-induced hepatotoxicity is the
disruption of delicate oxidant/antioxidant balance, which
can lead to liver injury via oxidative damage. Accumulat-
ing evidence has also shown that ROS generation induced
by D-gal is a major reason resulting in oxidative stress [25,
31]. In the present study, we showed that D-gal induced
overproduction of ROS in the mice and led to hepatic
oxidative damage, and the level of oxidative marker MDA,
which indicates the degree of lipid peroxidation, sig-
nificantly increased compared with normal controls.
FGF21 has been proven to prevent oxidative stress and
posses potent antioxidant/free radical-scavenging proper-
ties [16, 18, 33]. Our results showed that FGF21 decreased
the ROS production and MDA level in the liver of D-gal
mice, suggesting that FGF21 protects the liver against
oxidative stress induced by D-gal by decreasing ROS and
the lipid peroxide level. It is well known that the defense
system of antioxidant enzymes containing SOD, CAT,
GSH-Px, and so on may reduce oxidative stress and po-
tentially benefit oxidative-related diseases [34]. Oxidative
stress could enhance generation of free radical and impair
Fig. 3 Effect of FGF21 on the
production of ROS and the
parameters of oxidative stress in
the liver of D-gal-treated mice.
Normal controls were treated
with saline (0.9 %), and D-gal
mice were treated with D-gal
daily for 8 weeks. FGF21-
treated D-gal mice (D-
gal ? FGF21) were treated with
D-gal and simultaneously
administrated with FGF21 sc at
doses of 1 or 5 mg kg-1 d-1
once a day for 8 weeks. a ROS
were measured with 2,
7-dichlorofluorescein-diacetate
(DCFH-DA) fluorescence and
determined using Fluorescence
Microplate Reader (Perkin
Elmer, America). b, c MDA
level and SOD activity were
measured by commercial
detection kit using Microplate
Reader (Biotech Elx800). d–
f CAT, GSH-Px, and T-AOC
activities were measured by
commercial detection kit using
722 spectrophotometer. All data
are represented as mean ± SD,
n = 8 per group. *P \ 0.05,
**P \ 0.01 and ***P \ 0.001
versus D-gal group
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enzymatic antioxidant or non-enzymatic antioxidant. The
present study showed that the activities of antioxidant en-
zymes, including SOD, CAT, GSH-Px, and T-AOC, were
dramatically decreased in the liver of D-gal mice. Inter-
estingly, FGF21 could markedly renew the activities of
those antioxidants enzymes in the livers of D-gal mice.
The transcription factor Nrf2, which normally exists in
an inactive state as a consequence of binding to a cy-
toskeleton-associated protein, Keap1, can be activated by
redox-dependent stimuli. Alteration of the Nrf2-Keap1
interaction enables Nrf2 to translocate to the nucleus, bind
to the antioxidant-responsive element (ARE), and initiate
the transcription of genes coding for detoxifying enzymes
and cytoprotective proteins [35]. It has been reported that
Nrf2 is an important factor in controlling both constitutive
and inducible expression of a wide spectrum of an-
tioxidants and is responsible for protecting cells against
oxidative stress induced by D-gal in mice [36]. Our present
study showed that D-gal-induced decreased Nrf2 translo-
cation and its targeted antioxidant genes expression, such
Fig. 4 FGF21 induces nuclear
abundance of Nrf2 and
increases the levels of GSH and
the expression of antioxidant
genes in the liver of D-gal mice.
Normal controls were treated
with saline (0.9 %), and D-gal
mice were treated with D-gal
daily for 8 weeks. FGF21-
treated D-gal mice (D-
gal ? FGF21) were treated with
D-gal and simultaneously
administrated with FGF21 sc at
doses of 1 or 5 mg kg-1 d-1
once a day for 8 weeks. a The
protein levels of Nrf2 in the
nucleus were determined by
Western blot analysis. The
relative density is expressed as
the ratio Nrf2/Laminb1. The
bands were analyzed with
Image pro plus and the normal
control is set as 1.0. b Hepatic
levels of GSH were determined
by commercial detection kit
using Microplate Reader
(Biotech Elx800). c mRNA
expression of Sod2. d mRNA
expression of Gpx-1. e mRNA
expression of G6pdh. f mRNA
expression of GCL-c. The
mRNA expression was
quantified by real-time PCR.
Expression of each gene relative
to the expression of
housekeeping gene, b-actin was
analyzed and calculated as 2-
DDCt. All data are represented as
mean ± SD, n = 8 per group.
*P \ 0.05, **P \ 0.01 and
***P \ 0.001 versus D-gal
group
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as Sod2, Gpx-1, G6pdh, and GCL-c in the liver of mice.
Whereas administration of FGF21 is sufficient to reverse
these changes, suggesting that FGF21 protects mouse liver
against D-gal-induced oxidative stress by regulating the
activation of Nrf2 and Nrf2-mediated expression of an-
tioxidant genes. Recently, it has been demonstrated that
FGF21 is able to protect against Acetaminophen-induced
hepatotoxicity by enhancing PGC-1a/Nrf2-mediated an-
tioxidant capacity in the liver [22]. GSH, which has been
demonstrated to be regulated by Nrf2, is an important in-
tracellular antioxidant and redox potential regulator that
plays a vital role in drug detoxification and elimination and
in cellular protection from damage by ROS, peroxides, and
toxins [9, 37]. It is also reported that the initiation of
apoptosis is associated with the depletion of intracellular
GSH and the elevation of GSH level can protect cell from
apoptosis [38]. In the present study, the results showed that
GSH level decreased significantly in the liver of D-gal mice
comparing with normal controls, and administration of
FGF21 significantly increased hepatic GSH levels in a
dose-dependent manner.
PI3K/Akt signaling is known to protect a variety of cells
from apoptosis [25]. Akt, which is the primary mediator of
PI3K-initiated signaling, can be phosphorylated and
Fig. 5 FGF21 prevents D-gal-
induced apoptosis of
hepatocytes. Normal controls
were treated with saline
(0.9 %), and D-gal mice were
treated with D-gal daily for
8 weeks. FGF21-treated D-gal
mice (D-gal ? FGF21) were
treated with D-gal and
simultaneously administrated
with FGF21 sc at doses of 1 or
5 mg kg-1 d-1 once a day for
8 weeks. Liver apoptosis was
examined with TUNEL
staining. a Representative
micrographs of hepatic TUNEL
staining from mice in all groups,
Magnification, 10 9 20.
b Quantitative results of hepatic
TUNEL staining. All data are
represented as mean ± SD,
n = 8 per group. *P \ 0.05,
**P \ 0.01 and ***P \ 0.001
versus D-gal group
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Fig. 6 FGF21 regulates the
PI3K-Akt pathway and the
expression of caspase-3 and
pro-apoptotic proteins in the
liver of D-gal mice. Normal
controls were treated with saline
(0.9 %), and D-gal mice were
treated with D-gal daily for
8 weeks. FGF21-treated D-gal
mice (D-gal ? FGF21) were
treated with D-gal and
simultaneously administrated
with FGF21 sc at doses of 1 or
5 mg kg-1 d-1 once a day for
8 weeks. a, c, e, g, i Western
blots for PI3K, phospho-Akt
(Ser473), Bcl-2, Bax, and
caspase-3 of the liver in mice. b,
d, f, h, j Fold change in relative
density analysis of PI3K,
phospho-Akt (Ser473), Bcl-2,
Bax, and caspase-3 protein
bands. b-actin was probed as an
internal control in relative
density analysis of the protein
bands. The relative density is
expressed as the ratio (PI3K/b-
actin, phospho-Akt/Total-Akt,
Bcl-2/b-actin, Bax/b-actin, Bax/
b-actin, and caspase-3/b-actin).
The bands were analyzed with
Image pro plus and the vehicle
control is set as 1.0. Values are
averages from three
independent experiments.
k mRNA expression of P21. All
data are represented as
mean ± SD, n = 8 per group.
*P \ 0.05, **P \ 0.01 and
***P \ 0.001 versus D-gal
group
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activated at residues Ser473. It has been well established
that Akt acts as an anti-apoptotic signaling molecule in
many different cell death paradigms [39]. It has also been
reported that the PI3K/Akt pathway is involved in Nrf2-
dependent transcription [40]. In this study, we found that
the expression levels of PI3K p110 and Akt phosphoryla-
tion decreased in the liver of D-gal-treated mice. Admin-
istration of FGF21 significantly increased hepatic levels of
PI3K p110 and Akt phosphorylation in D-gal-treated mice,
suggesting that FGF21 could protect mouse liver by
regulating the PI3K-Akt signaling pathway.
PI3K/Akt signaling can up-regulate the expression of
Bcl-2, and activated Akt can also regulate cellular survival
and metabolism by binding and regulating many down-
stream effectors, such as Bcl-2 family proteins [41]. Bcl-2
family proteins, including Bcl-2 and Bax, play important
anti-apoptotic roles in the mitochondrial apoptotic pathway
and it can inhibit the release of cytochrome c from mito-
chondria into the cytosol. Once released, cytochrome c and
apoptotic peptidase activating factor 1 (Apaf-1) coassem-
ble in the presence of dATP to form the apoptosome which
induces caspase 9 dimerization and autocatalysis. Acti-
vated caspase 9 stimulates caspase 3 and subsequent cell
apoptosis [41]. In this study, our results showed that FGF21
significantly reduced the expression of Bax and increased
the expression of the anti-apoptotic protein Bcl-2 in the
liver of D-gal mice. Caspase is a family of proteins that are
main executors of the apoptotic process, which is a well-
identified downstream target for PI3K-Akt [12, 28]. Cas-
pase-3 plays a central role in the execution-phase of cell
apoptosis. Once activated, caspase-3 can in turn cleave
other protein substrates within the cell, and result in the
apoptotic process [42]. The present study showed that
FGF21 decreased the number of TUNEL-positive cells and
levels of activated caspase-3 in the livers of D-gal-treated
mice. ROS could activate caspase-3, thereby resulting in
apoptosis [42]. So our findings suggested that the inhibition
of caspase-3 activation might attribute to powerful ROS
scavenging and antioxidant activities of FGF21.
Conclusion
In summary, this study demonstrates for the first time that
FGF21 has potent protective effects against D-gal-induced
oxidative stress via activating Nrf2, which in turn triggers
PI3K/Akt-mediated apoptosis pathways in the mouse liver.
Hypothetic signaling pathway for FGF21 protecting against
D-gal-induced liver injury is illustrated in Fig. 7. This study
provides a novel insight into the mechanisms of FGF21 in
the protection of the liver.
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